Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLA | P06280 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 7/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | LMNA | P02545 | 4/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.52 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.52 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.52 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.52 |
| ▸ | PLIN1 | O60240 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 2/20 | 0.52 |
| ▸ | PLIN5 | Q00G26 | 2/20 | 0.52 |
| ▸ | ABHD5 | Q8WTS1 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | TNKS | O95271 | 1/20 | 0.52 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.52 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1736406 | 1.00 | GLA (0.58) | GLATDP1KMT2AMAPTALDH1A1 | |
| SCHEMBL29198288 | 0.89 | MAPT (0.59) | GLATDP1KMT2AMAPTALDH1A1 | |
| SCHEMBL10760753 | 0.86 | GLA (0.55) | GLATDP1KMT2AMAPTALDH1A1 | |
| SCHEMBL4122409 | 0.86 | GLA (0.55) | GLATDP1KMT2AMAPTALDH1A1 | |
| SCHEMBL6036031 | 0.85 | GLA (0.62) | GLATDP1KMT2AMAPTALDH1A1 | |
| SCHEMBL6036032 | 0.85 | GLA (0.62) | GLATDP1KMT2AMAPTALDH1A1 | |
| SCHEMBL775716 | 0.85 | MAPT (0.64) | GLATDP1KMT2AMAPTALDH1A1 | |
| SCHEMBL21803794 | 0.85 | MAPT (0.64) | GLATDP1KMT2AMAPTALDH1A1 | |
| SCHEMBL9247555 | 0.85 | MAPT (0.64) | GLATDP1KMT2AMAPTALDH1A1 | |
| SCHEMBL1721581 | 0.84 | GLA (0.60) | GLATDP1KMT2AMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7186416-B2 | Foamable pharmaceutical compositions and methods for treating a disorder | STIEFEL LABORATORIES, INC. (US) | 2007-03-06 | — | — | US | claimed |
| EP-1067896-B1 | TOPICAL COMPOSITIONS COMPRISING ASCORBYL-PHOSPHORYL-CHOLESTEROL | AVON PROD INC (US) | 2005-07-27 | — | — | EP | claimed |
| US-9827195-B2 | Fatty acid pharmaceutical foam | STIEFEL RESEARCH AUSTRALIA PTY LTD (AU) | 2017-11-28 | — | — | US | disclosed |
| US-20150209280-A1 | FATTY ACID PHARMACEUTICAL FOAM | STIEFEL RES AUSTRALIA PTY LTD (AU) | 2015-07-30 | — | — | US | disclosed |
| US-9023863-B2 | Fatty acid pharmaceutical foam | STIEFEL RESEARCH AUSTRALIA PTY LTD (AU) | 2015-05-05 | — | — | US | disclosed |
| EP-2046121-B1 | FATTY ACID PHARMACEUTICAL FOAM | STIEFEL RES AUSTRALIA PTY LTD (AU) | 2012-08-22 | — | — | EP | disclosed |
| EP-1633368-B1 | FOAMABLE PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING A DISORDER | STIEFEL LABORATORIES (US) | 2011-11-16 | — | — | EP | disclosed |
| WO-2011066182-A3 | SOCS3 INHIBITION PROMOTES CNS NEURON REGENERATION | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2011-10-27 | — | — | WO | disclosed |
| US-7829107-B2 | Foamable pharmaceutical compositions and methods for treating a disorder | STIEFEL LABORATORIES, INC. (US) | 2010-11-09 | — | — | US | disclosed |
| EP-2046121-A2 | FATTY ACID PHARMACEUTICAL FOAM | Stiefel Research Australia Pty Ltd (AU) | 2009-04-15 | — | — | EP | disclosed |
| WO-2008008397-A2 | FATTY ACID PHARMACEUTICAL FOAM | STIEFEL RESEARCH AUSTRALIA PTY LTD (AU) | 2008-01-17 | — | — | WO | disclosed |
| US-20050232957-A1 | Compositions and methods for moisturizing skin | TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA, THE | 2005-10-20 | — | — | US | disclosed |
| WO-2004105702-A2 | FOAMABLE PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING A DISORDER | STIEFEL LABORATORIES, INC. (US) | 2004-12-09 | — | — | WO | disclosed |
| US-20040241099-A1 | Foamable pharmaceutical compositions and methods for treating a disorder | CONNETICS CORPORATION | 2004-12-02 | — | — | US | disclosed |
| US-20040120990-A1 | Absorbent proteins and methods for using same | CUSHMAN JOHN C (US) | 2004-06-24 | — | — | US | disclosed |
| EP-1324681-A2 | ARTICLE FOR THE DELIVERY OF FOAM PRODUCTS | THE PROCTER & GAMBLE COMPANY (US) | 2003-07-09 | — | — | EP | disclosed |
| US-6547063-B1 | Article for the delivery of foam products | THE PROCTER & GAMBLE COMPANY | 2003-04-15 | — | — | US | disclosed |
| WO-2002030237-A2 | ARTICLE FOR THE DELIVERY OF FOAM PRODUCTS | THE PROCTER & GAMBLE COMPANY (US) | 2002-04-18 | — | — | WO | disclosed |
| US-6283336-B1 | Article for the delivery of foam products | THE PROCTER & GAMBLE COMPANY | 2001-09-04 | — | — | US | disclosed |
| US-5629301-A | Use of salicylic acid for regulating skin wrinkles and/or skin atrophy | RICHARDSON-VICKS INC. (US) | 1997-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150209280-A1 | FATTY ACID PHARMACEUTICAL FOAM | FASN, FFAR3, FFAR1 | GLA 1170/4885TDP1 1111/4885KMT2A 4288/4885 |
| US-20040241099-A1 | Foamable pharmaceutical compositions and methods for treating a disorder | CLN6, CYP27A1, CYP46A1 | GLA 1711/4885TDP1 533/4885KMT2A 4718/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.